10-K: Theriva Biologics Reports Positive Cancer Trial, Strategic Shift

Theriva Biologics announced positive Phase 2b pancreatic cancer trial results for VCN-01 and a strategic shift to focus on oncology, while licensing out its SYN-020 asset.

Summary

• Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, having transitioned its strategic focus to oncology in March 2022.
• The lead product candidate, VCN-01 (zabilugene almadenorepvec), an oncolytic human adenovirus, has shown positive topline data in the VIRAGE Phase 2b clinical trial for metastatic pancreatic ductal adenocarcinoma (mPDAC).
• In the VIRAGE trial, VCN-01 combined with standard-of-care (SoC) chemotherapy resulted in a median Overall Survival (OS) of 10.8 months, compared to 8.6 months for SoC alone (Hazard Ratio = 0.57, p=0.0546).
• Progression-Free Survival (PFS) also improved to a median of 7.0 months with VCN-01+SoC, versus 4.6 months for SoC alone (Hazard Ratio = 0.55, p=0.0105).
• The median Duration of Response (DoR) doubled to 11.2 months in the VCN-01+SoC arm, compared to 5.4 months in the SoC arm (Hazard Ratio = 0.22, p=0.0035).
• Patients receiving two doses of VCN-01 and four or more cycles of SoC chemotherapy showed an even greater increase in median OS to 14.8 months, compared to 11.6 months for SoC alone (HR=0.44, p=0.046).
• VCN-01 has received Orphan Drug designation from the FDA for pancreatic cancer (June 2023) and retinoblastoma (February 2022), and Fast Track designation for pancreatic cancer (May 2024).
• The company entered into a license agreement with Rasayana Therapeutics, Inc. in February 2026, granting an exclusive worldwide license for SYN-020, an oral intestinal alkaline phosphatase enzyme.
• Under the Rasayana License Agreement, Theriva received an upfront payment of $300,000 and is eligible for up to $16.0 million in development milestones and $22.0 million in sales milestones, plus tiered royalties.
• As part of its strategic transformation, Theriva is exploring value creation options for its SYN-004 asset, including out-licensing or partnering, and does not intend to fund its further internal development.
• The company implemented a workforce reduction of seven employees (32% of its global workforce) on September 30, 2025, incurring $520,000 in charges but expecting $1.8 million in annual compensation and benefits savings.
• Theriva Biologics reported a net loss of $23.7 million for the year ended December 31, 2025, compared to $25.7 million in 2024, and an accumulated deficit of $358.7 million as of December 31, 2025.
• Cash and cash equivalents were $13.1 million as of December 31, 2025, and approximately $15.1 million as of early March 2026, with a projected cash runway into the first quarter of 2027.
• The company's auditors included an explanatory paragraph regarding its ability to continue as a going concern due to recurring losses and net capital deficiency.
• Theriva raised approximately $6.8 million in net proceeds from ATM sales in 2025 and $2.3 million in Q1 2026, and $3.9 million in net proceeds from a warrant inducement in October 2025.
• A $5.0 million milestone payment to Grifols, earned from the VCN acquisition, has been deferred pending ongoing discussions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report. The positive clinical trial results for VCN-01 in pancreatic cancer are a significant de-risking event and a major step forward for the company's new oncology focus. The strategic licensing of SYN-020 also demonstrates prudent capital management. However, the persistent 'going concern' warning and the substantial need for future capital for pivotal trials remain critical challenges.

Positives

• VCN-01 VIRAGE Phase 2b clinical trial met its primary survival and safety endpoints, demonstrating improved Overall Survival (OS), Progression-Free Survival (PFS), and Duration of Response (DoR) in metastatic pancreatic cancer patients.
• VCN-01 received Fast Track Designation from the FDA for pancreatic cancer, potentially expediting its development and review process.
• VCN-01 holds Orphan Drug designation from both the FDA and EMA for pancreatic cancer and retinoblastoma, offering potential market exclusivity and other benefits.
• The licensing agreement for SYN-020 with Rasayana Therapeutics provides an upfront payment of $300,000 and potential future development and sales milestones up to $38.0 million, allowing Theriva to derive value without further capital investment.
• The THERICEL project, a proprietary suspension cell line for viral manufacturing, received 2.28 million Euros (approx. $2.54 million) in government funding, supporting scale-up and potential GMP manufacture.
• The workforce reduction is expected to save approximately $1.8 million in compensation and benefits annually, extending the cash runway into the first quarter of 2027.

Negatives

• The company has a significant accumulated deficit of $358.7 million as of December 31, 2025, and has experienced recurring losses from operations since inception.
• The independent registered public accounting firm's report includes an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern without additional capital.
• Current cash is only sufficient to fund operations into the first quarter of 2027 and will not cover additional trials for VCN-01 or SYN-004, or the completion of the last cohort of the SYN-004 Phase 1b/2a clinical trial.
• A $5.0 million contingent consideration payment to Grifols, which has been earned, has been deferred pending ongoing discussions, indicating potential liquidity strain.
• The company implemented a workforce reduction of 32% of its global workforce, which, while intended to save costs, reflects ongoing financial pressures.
• Past material weaknesses in internal controls were identified in 2023 and the first three quarters of 2024, although management believes they were remediated by December 31, 2024.

Risks

• Ability to continue as a going concern is dependent on obtaining additional equity or debt financing, achieving operating efficiencies, reducing expenditures, and generating revenue.
• Failure to obtain additional funding when needed may force delays, reductions, or elimination of development programs or commercialization efforts, leading to significant stockholder dilution if equity is issued.
• Limited operating history as an oncology company with no products approved for commercial sale and no significant source of revenue, making future success uncertain.
• Research and development efforts may not result in commercially successful products and technologies, limiting profitability.
• Reliance on third parties for product manufacturing and clinical trials, with potential for delays, supply shortages, or non-compliance with regulations.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, with no assurance of successful outcomes or regulatory approval.
• Patients administered product candidates may experience unexpected side effects or safety risks, potentially halting development or limiting commercial potential.
• Inability to obtain or maintain orphan drug designation or exclusivity, which could limit profitability.
• Fast Track designation does not guarantee faster development, review, or approval, nor does it assure FDA approval.
• Eligibility for a Rare Pediatric Disease Priority Review Voucher for VCN-01 for retinoblastoma is contingent on FDA approval by September 30, 2029, and meeting other criteria.
• Product candidates, if approved, may not gain acceptance among physicians, patients, and the medical community, impeding sales.
• Lack of an in-house marketing, sales, or distribution organization, requiring reliance on third parties or significant capital expenditure to build one.
• Uncertainty regarding adequate coverage and reimbursement from third-party payors for product candidates, which could impede sales and profitability.
• Healthcare reform measures, such as the Inflation Reduction Act, could adversely affect product pricing and reimbursement.
• Failure to comply with state and federal healthcare regulatory laws could result in substantial penalties, damages, fines, and operational curtailment.
• Risks associated with international operations, including different regulatory requirements, reduced intellectual property protection, and economic instability.
• Inherent risk of product liability lawsuits, potentially leading to substantial liabilities and commercialization limitations.
• Changes to U.S. and foreign tax laws or differing interpretations could adversely affect business and operating results.
• Reliance on patents, patent applications, trade secrets, and regulatory exclusivities to protect product candidates, with risks of invalidation, infringement by others, or substantial litigation costs.
• Volatility in the market price of common stock, influenced by various factors unrelated to operating performance, and potential for significant dilution from future capital raises.
• Anti-takeover effects of corporate charter, bylaws, and Nevada law could discourage or delay changes in control.
• Extensive reliance on information technology systems, vulnerable to cybersecurity threats, system failures, and data breaches.
• Global health crises (e.g., COVID-19) or other disruptions to global trade and supply lines may adversely affect planned operations and clinical trials.
• Unfavorable U.S. or global economic conditions, including inflation and geopolitical instability, could adversely affect business, financial condition, or results of operations.

Future Outlook

The company plans an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial for VCN-01 in metastatic pancreatic cancer. EMA Scientific Advice supports a single, high-quality, double-blinded, randomized, placebo-controlled Phase 3 trial. The company also anticipates commencing and completing a potential Phase 2a study evaluating VCN-01 dosing frequency and continuing preclinical studies for VCN-01 and VCN-12. Development of SYN-004 is contingent on securing grant funding or a strategic partnership, as the company does not intend to fund it internally. The cash runway is expected to extend into the first quarter of 2027, but significant additional capital will be required for future clinical trials.

Management Comments

• Management believes the arrangement with Rasayana Therapeutics will provide potential to derive value from the SYN-020 asset without the need for continued investment, allowing focus on oncology assets.
• Management believes the workforce reduction plan will direct resources towards business development, licensing, clinical trial planning, VCN-01 manufacturing scale-up, limited preclinical activities, and regulatory interactions, representing the best opportunity for success.
• Management expects the current cash to fund operations into the first quarter of 2027, but acknowledges that no assurances can be provided and cash could differ materially from expectations based on various factors.

Industry Context

StockSavvy.ai notes that Theriva Biologics operates in the highly competitive pharmaceutical and biotechnology industries, particularly within the rapidly evolving oncolytic virotherapy (OV) and microbiome sectors. The OV market has seen limited approvals (Amgen's Imlygic, Daiichi Sankyo's DELYTACT, Shanghai Sunway Biotech's Oncorine), with Replimune and CG Oncology also advancing candidates. Theriva's VCN-01, engineered for intravenous delivery, tumor-selective replication, and expression of PH20 hyaluronidase, aims to differentiate itself by enhancing tumor penetration and immune response, potentially overcoming limitations of other OVs that require direct injection. The company's shift to oncology and licensing of its GI assets reflects a common industry trend of specialization to optimize resource allocation in capital-intensive drug development.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on the business, operating results, financial condition, or cash flows.

Related Party Transactions

• MaryAnn Shallcross, wife of CEO Steven Shallcross, received $202,000 in compensation expense (including salary and an option grant valued at $27,000) during the year ended December 31, 2025. Her employment was terminated on September 30, 2025, as part of the workforce reduction, and she received a separation package including three months of base salary, accelerated vesting of unvested equity, and an extended option exercise period until December 31, 2026.

Stakeholder Impact

• Shareholders face potential dilution from future equity financings and continued stock price volatility, but may benefit from the positive clinical trial results and strategic focus on oncology.
• Employees experienced a significant workforce reduction (32% of global workforce), impacting job security for some, while remaining employees are focused on key oncology development.
• Customers (future patients) may benefit from the continued development of VCN-01 for metastatic pancreatic cancer and retinoblastoma, addressing high unmet medical needs.
• Creditors face risks associated with the company's 'going concern' uncertainty and its need for substantial additional capital to fund operations and clinical trials.

Next Steps

• Plan an End-of-Phase 2 meeting with the FDA in the first half of 2026 to finalize the design of a pivotal multinational Phase 3 clinical trial for VCN-01 in metastatic pancreatic cancer.
• Commence and complete a potential Phase 2a study evaluating VCN-01 dosing frequency.
• Conduct exploratory VCN-01 manufacturing scale-up activities.
• Continue regulatory interactions regarding proposed VCN-01 clinical trials in PDAC and retinoblastoma.
• Continue preclinical studies supporting VCN-01 and VCN-12 (first candidate from VCN-X discovery program).
• Actively pursue additional equity or debt financing opportunities, including private placements or public offerings, and strategic partnerships/collaborations.
• Explore value creation options for the SYN-004 asset, including out-licensing or partnering, as internal funding for its further development is not anticipated.

Key Dates

Recommendation

The positive Phase 2b clinical trial results for VCN-01 in metastatic pancreatic cancer are a significant positive, demonstrating potential efficacy in a high-unmet-need area. The strategic licensing of SYN-020 also shows a disciplined approach to capital allocation. However, the company's recurring losses, substantial accumulated deficit, and the explicit 'going concern' warning from auditors present considerable financial risk. While the clinical progress is encouraging, the need for significant additional capital to fund pivotal trials and the inherent volatility of a clinical-stage biotech stock suggest a 'hold' recommendation. Investors should monitor future financing activities and the progress of VCN-01's next clinical stages closely.

Keywords

Oncology, Biologics, VCN-01, Pancreatic Cancer, Retinoblastoma, Oncolytic Virus, Clinical Stage, FDA Fast Track, Orphan Drug, SYN-020, Rasayana Therapeutics, License Agreement, Biopharmaceutical, Clinical Trials, SEC Filing, 10-K, Going Concern, Capital Raise, Biotechnology